The Massachusetts Life Sciences Refundable § 38M Research Tax Credit: A Comprehensive Analysis of Statutory Frameworks, Administrative Guidance, and Strategic Implementation

The Massachusetts Life Sciences Refundable § 38M Research Tax Credit is a specialized tax mechanism that allows certified life sciences companies to receive a 90% cash refund on unused portions of their earned research and development credits. This provision transforms traditionally non-refundable corporate tax credits into immediate liquidity, providing essential non-dilutive capital for high-growth ventures in the biotechnology, medical device, and diagnostics sectors. 1

This incentive represents a sophisticated intersection of the general Massachusetts research credit landscape and the targeted economic goals of the Massachusetts Life Sciences Center (MLSC). By understanding the nuances of Section 38M in the context of the Life Sciences Tax Incentive Program, corporations can effectively bridge the financial gap between early-stage innovation and commercial viability. This report explores the legislative origins, technical calculation methodologies, local revenue office guidance, and strategic implications of this vital fiscal tool. 4

Legislative Context and the Evolution of Life Sciences Policy

The current landscape of life sciences taxation in Massachusetts is the result of nearly two decades of targeted legislative efforts to maintain the Commonwealth’s position as a global leader in innovation. The foundation of this effort is the Massachusetts Life Sciences Act, a $1 billion initiative signed into law in June 2008. 7 This Act established the MLSC as a quasi-public agency tasked with administering a suite of incentives to stimulate research, development, and manufacturing. 4

Since its inception, the program has undergone several significant renewals and expansions. In 2018, Governor Charlie Baker signed legislation providing an additional $623 million in bond authorization and tax credits. 7 Most recently, in November 2024, Governor Maura Healey signed “An Act relative to strengthening Massachusetts’ economic leadership,” often referred to as the Mass Leads Act. 7 This legislation extended the life sciences initiative for another ten years and increased the annual statutory cap for tax incentives from $30 million to $40 million, reflecting the state’s commitment to scaling the industry in the face of increasing global competition. 8

The legislative intent behind § 38M(j) is to address the unique financial profile of life sciences companies, which often endure a “valley of death”—a period of intense R&D spending with no immediate revenue or tax liability. 7 By allowing for the refundability of research credits, Massachusetts ensures that these companies can reinvest their tax benefits into hiring and infrastructure long before they become profitable. 12

The General Massachusetts Research Credit Framework (§ 38M)

To understand the refundable life sciences credit, one must first master the underlying mechanics of the general Massachusetts Research Credit, governed by M.G.L. c. 63, § 38M. This credit is available to all business corporations subject to the corporate excise tax that incur qualified research expenses (QREs) in Massachusetts. 2

Statutory Alignment with Federal IRC Section 41

The Massachusetts credit is modeled closely after the federal research credit under Section 41 of the Internal Revenue Code (IRC). 5 However, the Commonwealth maintains specific requirements:

• In-State Activities: Only research activities conducted within the geographic boundaries of Massachusetts qualify for the credit. 5
• Qualified Expenses: These include wages for employees performing or supporting research, supplies consumed during the research process, and contract research payments (subject to the standard 65% limitation for payments to third parties). 5
• Technological Uncertainty: Research must be intended to eliminate uncertainty regarding the development or improvement of a business component. 5

The Limitation of Non-Refundability

For general corporations, the § 38M credit is strictly non-refundable and subject to the 75% excise tax limitation. 2 A corporation can use the credit to offset 100% of its first $25,000 in excise liability, but only 75% of the liability in excess of $25,000. 2 Furthermore, the credit cannot reduce the corporate excise below the statutory minimum of $456. 5

Unused credits can be carried forward for 15 years, or indefinitely if the credit was disallowed specifically due to the 75% limitation rule. 5 For most sectors, these credits accumulate as long-term deferred tax assets. For the life sciences sector, § 38M(j) provides the mechanism to unlock this value immediately. 3

The Life Sciences Refund Election: Mechanics and Eligibility

The refundability of the § 38M credit is not automatic; it is a discretionary benefit awarded through the MLSC Tax Incentive Program. 3 This program allows a “certified life sciences company” to apply for a refund of 90% of its excess research credits in lieu of carrying them forward. 2

Certification Requirements

To be eligible for the refund, a company must first achieve and maintain certification from the MLSC. This process involves a competitive application that evaluates the company’s potential for job creation and economic impact. 13

1. Life Sciences Definition: The company must meet the definition of “life sciences” under M.G.L. c. 23I, § 2, which includes biotechnology, medical devices, diagnostics, and digital health. 2
2. Registration and Standing: The company must be registered to do business in Massachusetts and be in good standing with the Department of Revenue (DOR), the Secretary of the Commonwealth, and the Department of Unemployment Assistance. 8
3. Headcount Minimums: Most application rounds require the company to employ at least 10 permanent full-time employees in Massachusetts at the time of application. 12
4. Job Creation Commitments: Awardees must commit to creating and retaining a specific number of new jobs over a multi-year period (generally three to five years). 9

12

The “Refundable” vs. “Non-Refundable” Distinction in Life Sciences

It is important to clarify that Massachusetts offers two distinct research credits for life sciences companies. While both are based on research spending, their treatment differs significantly:

• Section 38M (The General Credit): This is the credit that can be made refundable at 90% if the company receives an MLSC award. 1
• Section 38W (The Life Sciences Research Credit): This is a separate credit available for certain expenses that might not qualify under § 38M, such as clinical trials conducted outside the state. 1 Crucially, § 38W is non-refundable but offers a 15-year carryforward. 1

Technical Calculation Methodologies

The amount of the § 38M credit—and thus the potential refund—depends on the calculation method elected by the taxpayer. Massachusetts provides two options: the Traditional Method and the Alternative Simplified Method (ASM). 2

The Traditional Method

The Traditional Method calculates the credit based on incremental growth over a historical base. The credit equals:

$$10\% \times (\text{Qualified Research Expenses} – \text{Base Amount}) + 15\% \times (\text{Basic Research Payments})$$

The Base Amount is a complex variable calculated by multiplying the taxpayer’s average annual gross receipts for the four preceding years by a “fixed-base ratio.” 2 This ratio is determined by the relationship between research expenses and gross receipts during a specific historical period (generally 1984-1988 for established firms). 15 The base amount can never be less than 50% of the current year’s QREs. 2

The Alternative Simplified Method (ASM)

For taxable years starting in 2015, corporations can elect the ASM, which is often more beneficial for rapidly scaling biopharma startups that may lack historical gross receipts or have highly volatile R&D budgets. 5

Under the ASM for 2021 and beyond, the credit is equal to:

$$10\% \times (\text{Current Year QREs} – 50\% \times \text{Average QREs for the prior 3 years})$$

If a taxpayer did not have QREs in any of the three preceding years, the credit is calculated as 5% of the current year’s QREs. 2 The ASM election is generally considered a long-term choice and should not be changed annually without significant justification. 5

Local Revenue Office Guidance: TIR 08-23 and TIR 13-6

The Massachusetts Department of Revenue has issued two primary Technical Information Releases (TIRs) that provide the authoritative interpretation of how the life sciences refund applies to the law.

TIR 08-23: Strategic Implementation

TIR 08-23 explains that the Life Sciences Tax Incentive Program is competitive and that the MLSC, in consultation with the DOR, has the authority to “limit any incentive or incentives to specific dollar amounts or time duration.” 4 This establishes the “Award” system: a company does not simply get a refund for all its credits; it gets a refund only for the amount authorized by the MLSC for that specific tax year. 3

This guidance also clarifies the carryover trade-off. If a taxpayer elects to receive a refund, the carryover provisions for the credit are waived. 2 Effectively, the company is selling its credit back to the state at a 10% discount to gain immediate cash flow. 3

TIR 13-6: The “Lesser Of” Calculation and Recapture Rules

TIR 13-6 provides the technical formula for the refund. It stipulates that the refund authorized under § 38M(j) is the lesser of:

1. 90% of the gross award amount specified in the Tax Incentive Agreement with the MLSC. 17
2. 90% of the company’s “available excess credits” (those credits remaining after the 75% excise tax limitation is applied). 17

This ensures that the state never pays a refund that exceeds what the company actually earned through its research spend, nor does it exceed the budget allocated to that company by the MLSC. 3

TIR 13-6 also details the Recapture process. If a company is “decertified”—usually for failing to meet its job creation targets—the DOR can recapture the tax benefits previously granted. 7 The recaptured amount is added as “additional tax due” on the company’s return for the year in which the certification is revoked. 17 Interestingly, a decertified company can use its non-refundable research credit carryforwards to pay off this recapture liability, which provides a small measure of protection for firms that fail despite significant R&D efforts. 17

Detailed Example: BioVentures Inc.

To illustrate the interaction of these rules, consider BioVentures Inc., a certified life sciences company with the following profile for the 2024 tax year:

• MLSC Award: Authorized to receive a refund of up to $200,000 in excess § 38M research credits. 3
• Research Spending: $3,000,000 in QREs in Massachusetts.
• ASM Calculation: Average QREs for 2021-2023 were $2,000,000.

• Credit = $10\% \times (\$3,000,000 – (50\% \times \$2,000,000)) = \$200,000$. 2

• Corporate Excise Liability: $25,000.

• BioVentures uses $25,000 of its credit to reduce its excise to the minimum of $456 (using $24,544 of the credit). 5

• Available Excess Credit: $\$200,000 – \$24,544 = \$175,456$. 3

Applying the TIR 13-6 “Lesser Of” Rule:

1. 90% of the MLSC Award ($200,000 \times 0.90$) = $180,000.
2. 90% of Available Excess ($175,456 \times 0.90$) = $157,910.

BioVentures Inc. receives a cash refund of $157,910. The remaining 10% of the excess credits ($17,546) is forfeited and cannot be carried forward. 4

Administrative Compliance and Filing Procedures

Claiming the refundable credit requires precise coordination between tax filing and MLSC reporting. 3

Tax Forms and Schedules

• Schedule RC: Used to calculate the total earned research credit for the year. Corporations must check the box for either the Traditional Method or the ASM. 5
• Schedule RLSC (Refundable Life Science Credit): This is the primary form for certified companies. 3

• Part 1: Tracks the total credits authorized by the MLSC and those used to reduce the current year’s tax liability. 3
• Part 2: Specifically calculates the 90% refund amount based on the “lesser of” logic described in TIR 13-6. 3

• Schedule CMS (Credit Manager Schedule): This schedule tracks all credits, their usage, and their carryover status. Refunded credits must be clearly identified here to ensure they are not inadvertently carried forward. 3

MLSC Annual Reporting

Recipients of tax awards must file an annual report with the MLSC within 30 days of the end of each calendar year. 7 This report must certify whether the company has met its job creation and retention targets. 7 Failure to file this report, or failure to meet the targets, triggers a review process that could lead to decertification and recapture of the 90% refund. 7

Economic Impact and Ecosystem Significance

The § 38M refundable credit is a cornerstone of the Massachusetts life sciences ecosystem. 12 The strategic significance of this credit extends beyond individual tax savings; it serves as a macro-economic tool for state-level competitiveness. 7

Statistics on Award Distribution

According to the MLSC’s recent annual reports and the Healey-Driscoll Administration’s announcements, the Tax Incentive Program has achieved significant scale:

• Total Awards: Over 459 awards have been granted since 2008. 13
• Total Funding: Approximately $365 million has been awarded in tax incentives. 13
• Job Impact: More than 20,700 jobs have been committed through the program. 9
• Geographic Reach: In the most recent rounds, 98% of new jobs were created in communities outside of Boston and Cambridge, demonstrating the program’s success in decentralizing the industry. 9

In 2024 alone, the program allocated $21.4 million to nineteen companies, creating 1,155 new jobs across the state. 21 Major recipients in recent cycles include AbbVie ($1.53 million for 60 jobs), Medtronic ($4.85 million for 220 jobs), and Insulet Corporation ($1.52 million for 83 jobs). 9

Strategic Advantage for Startups

For early-stage biotech firms, the refundable credit is often the difference between continuing a clinical trial and pausing operations. 7 Unlike grant funding, which can be restrictive in its use, or venture capital, which requires giving up equity, the refundable tax credit is a reward for research activities that have already occurred. 12 This allows founders to maintain greater control over their companies while fueling the high-risk, high-reward research that characterizes the industry. 14

Conclusion: Bridging the Gap in Life Sciences Finance

The Massachusetts Life Sciences Refundable § 38M Research Tax Credit is a vital component of the state’s innovation policy. By integrating the broad definitions of the federal research credit with the targeted administrative oversight of the MLSC, Massachusetts has created a mechanism that rewards both scientific discovery and economic growth. 5

For corporations, the path to maximizing this benefit requires a sophisticated understanding of both the “earned” credit (the § 38M calculation) and the “awarded” refund (the MLSC certification and award). Success necessitates meticulous record-keeping of R&D expenses, proactive management of headcount targets to avoid recapture, and precise compliance with DOR filing requirements. 3

As the Mass Leads Act of 2024 increases the resources available for these incentives, the importance of the refundable § 38M credit will only grow. It remains a powerful testament to the Commonwealth’s strategy: supporting the life sciences not just in the lab, but through a robust and responsive fiscal framework that understands the unique needs of the industry. 7

R&D Tax Credit Preparation Services

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.

If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services

creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees

Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/